MAIA Biotechnology, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | $0 | $0 | $0 | — |
| Research and development | $453,745 | $10.0M | $11.1M | $8.9M | $3.5M |
| Operating expenses | $24.3M | $17.0M | $20.2M | $16.2M | $7.8M |
| Operating income | -$24.3M | -$17.0M | -$20.2M | -$16.2M | -$7.8M |
| Interest expense | — | $57 | $6,863 | $6,967 | $827,539 |
| Pretax income | -$22.4M | -$23.3M | -$19.8M | -$15.8M | -$12.6M |
| Income tax expense | $2,000 | $2,000 | — | — | — |
| Net income | -$22.4M | -$23.3M | -$19.8M | -$15.8M | -$12.6M |
| Balance Sheet | |||||
| Cash and equivalents | $0 | $0 | $0 | $0 | $0 |
| Current assets | $9.7M | $10.2M | $7.6M | $11.8M | $10.7M |
| Total assets | $9.7M | $10.2M | $7.6M | $12.0M | $11.3M |
| Current liabilities | $5.8M | $3.8M | $4.9M | $3.3M | $2.1M |
| Total liabilities | $7.3M | $6.5M | $7.1M | $3.5M | $2.1M |
| Stockholders' equity | $2.4M | $3.6M | $477,511 | $8.5M | $9.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$18.8M | -$15.7M | -$13.1M | -$12.1M | -$4.1M |
| Stock-based compensation | $2.6M | $1.9M | $3.1M | $2.3M | $2.7M |
Shares outstanding 60.8M · Free float 61.3%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.